OOIR: Observatory of International Research

Papers

(The TQCC of Lancet Respiratory Medicine is 15. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Savolitinib in NSCLC: progress in the MET exon 14 journey	934
Impact of Myanmar's earthquake on respiratory health	587
FLiRTing with danger as SARS-CoV-2 variants evolve	506
Predicted bodyweight—a misleading metric for tidal volume titration?	475
Optimising trial design for cardiogenic shock: insights from the sixth Critical Care Clinical Trialists Workshop	359
Top ten research priorities for breathlessness research: UK James Lind Alliance priority setting partnership	297
Interstitial lung disease: a decade of progress and hope	296
Predatory publishers appear in PubMed (and your inbox)	280
First results from the international paediatric bronchiectasis registry (Child-BEAR-Net Registry) describing multicountry variations in childhood bronchiectasis and its management: a multicentre, cros	251
Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials	246
Thoracentesis: an old story and some new sources	232
Risk factors for COVID-19-associated pulmonary aspergillosis: a systematic review and meta-analysis	230
Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial	228
Why has the incidence of tuberculosis not reduced in London during the COVID-19 pandemic?	209
Correction to Lancet Respir Med 2019; 7: 745–56	203
GOLD report: 2022 update	196
Concerns about PRISm	192
The burden of tuberculosis in Libya	184
Broad protection from SARS-CoV-2 variants without antigen matching	183
Bedaquiline, pretomanid, and linezolid with or without moxifloxacin for tuberculosis	183
US Senate committee investigates asthma inhaler prices	179
Major gaps in childhood pneumonia research priorities remain	178
Rituximab for connective tissue disease-associated interstitial lung disease	173
European Society of Intensive Care Medicine (ESICM) LIVES 35th Annual Congress	168
Australia bans engineered stone to prevent silicosis	168

Opioids bring peace to patients with IPF cough	162
Chronic obstructive pulmonary disease: 10 years of precision-guided success	161
Correction to Lancet Respir Med 2024; 12: 129–40	161
Video laryngoscopy is not the nemesis of direct laryngoscopy	160
European Respiratory Society International Congress 2022	159
Eat or heat: fuel poverty and childhood respiratory health	157
Concerns regarding a suggested long COVID paradigm – Authors' reply	157
Predictors and associations of the persistent airflow limitation phenotype in asthma: a post-hoc analysis of the ATLANTIS study	154
The course of action for effective anti-cytokine treatment in COVID-19	154
Postoperative CPAP after major abdominal surgery	152
One-off low-dose CT for lung cancer screening in China: a multicentre, population-based, prospective cohort study	149
Advancing precision medicine for acute respiratory distress syndrome	146
Long COVID: systemic inflammation and obesity as therapeutic targets	146
Overcoming barriers to scaling up tuberculosis preventive treatment for household contacts	145
Challenges of modulating the risk of bronchopulmonary dysplasia in clinical trials	145
Correction to Lancet Respir Med 2025; 13: 244–55	142
Correction to Lancet Respir Med 2021; 9: 1275–87	141
Patient with cystic fibrosis not diagnosed until age 23 years now treated with the new triple therapy Trikafta	140
Transbronchial cryobiopsy followed by as-needed surgical lung biopsy versus immediate surgical lung biopsy for diagnosing interstitial lung disease (the COLD study): a randomised controlled trial	137
Trump administration decimates worker health oversight	136
Association of SARS-CoV-2 infection and persistence with long COVID	135
Evaluation of the effect of multimorbidity on difficult-to-treat asthma using a novel score (MiDAS): a multinational study of asthma cohorts	134
Chronic cough as a disease: implications for practice, research, and health care	134
Preoxygenation strategies for intubation of patients who are critically ill: a systematic review and network meta-analysis of randomised trials	133
Effectiveness of preventive treatment among different age groups and Mycobacterium tuberculosis infection status: a systematic review and individual-participant data meta-analysis of contact tracing s	133
Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial	130
Perioperative lung expansion and pulmonary outcomes after open abdominal surgery versus usual care in the USA (PRIME-AIR): a multicentre, randomised, controlled, phase 3 trial	130
Ceftriaxone to prevent early ventilator-associated pneumonia in patients with acute brain injury: a multicentre, randomised, double-blind, placebo-controlled, assessor-masked superiority trial	128
Health effects of gas fuels: interpreting evidence from a comprehensive meta-analysis	127
Sarcoidosis and fatigue: there is a useful cognitive treatment? – Authors' reply	126
Correction to Lancet Respir Med 2022; 10: 972–84	126
Claudio Castanos—leader in cystic fibrosis care in Argentina	125
Nasally delivered SARS-CoV-2 vaccines: future promise and challenges	120
Priorities for NICE in health and social care	119
Nintedanib for treating progressive fibrosing interstitial lung diseases	119
Vaccination in the world's top athletes	118
US EPA signals renewed regulatory scrutiny of toxic air pollution	117
Genetic associations and lung function in IPF: unexpected answers, persistent questions	114
Solid and semi-solid perspectives in thoracic surgery	113
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CRO	112
Extracorporeal cardiopulmonary resuscitation: not why, but how	112
Awake prone positioning in COVID-19: is tummy time ready for prime time?	112
Early Th2 inflammation in the upper respiratory mucosa as a predictor of severe COVID-19 and modulation by early treatment with inhaled corticosteroids: a mechanistic analysis	111
Improving lifelong respiratory health after preterm birth	110
Endoscopic sinus surgery with medical therapy versus medical therapy for chronic rhinosinusitis with nasal polyps: a multicentre, randomised, controlled trial	110
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, doub	105
Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis	104
Lung epithelial and myeloid innate immunity in influenza-associated or COVID-19-associated pulmonary aspergillosis: an observational study	104
Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, co	103
Comparative vaccine effectiveness against severe COVID-19 over time in US hospital administrative data: a case-control study	101

Unveiling a hidden phenotype of early tuberculosis	100
Health effects from climate-driven events: lessons learnt	99
Azithromycin therapy for prevention of chronic lung disease of prematurity (AZTEC): a multicentre, double-blind, randomised, placebo-controlled trial	98
Spirometry in female individuals – Authors' reply	98
Choice overload for RSV prevention—how to form your opinion	98
Pooled testing for TB: revisiting a cost-saving innovation	97
Management after combined BPA and medical therapy in CTEPH: time for cardiopulmonary exercise testing	96
Pre-COPD: an evolving concept with practice potential	95
Unavailability of varenicline: a global tragedy for the fight against the tobacco epidemic	95
Realignment of clinical research after the COVID-19 era	94
Individualised, perioperative open-lung ventilation strategy during one-lung ventilation (iPROVE-OLV): a multicentre, randomised, controlled clinical trial	94
Clean air, climate targets, and respiratory health in Europe	94
Tackling tuberculosis: what lies beneath the surface?	92
NICE guidance on nivolumab plus ipilimumab for untreated, unresectable malignant pleural mesothelioma	90
Determinants of long-term outcomes in patients with COVID-19 supported with ECMO	89
Correction to Lancet Respir Med 2023; 11: 1064–74	88
Developments and priorities in bronchiectasis research	87
Venus and Mars: chest wall deformity and thoracic disease	86
COPD: a complex, multifactorial, but preventable disease?	86
COP27 Climate Change Conference: urgent action needed for Africa and the world	85
Underappreciated causes of obstructive lung disease	83
Opioid use and sleep apnoea	81
Liberal or restrictive transfusion for VV ECMO	78
Trouble with promoting lung cancer screening in never-smokers	78
Prevalence of sleep-disordered breathing in an African general population: The Benin Society and Sleep (BeSAS) study	77
Predicting the future risk of lung cancer: development, and internal and external validation of the CanPredict (lung) model in 19·67 million people and evaluation of model performance against seven ot	76
Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials	76
Validation and utility of ARDS subphenotypes identified by machine-learning models using clinical data: an observational, multicohort, retrospective analysis	74
Early-life respiratory syncytial virus disease and long-term respiratory health	74
Collateral caring	72
The role of small airway dysfunction in asthma control and exacerbations: a longitudinal, observational analysis using data from the ATLANTIS study	72
Treating acute respiratory illness: the need to be proactive	71
The recent explosion in snortable energy powder consumption	70
Wildfires in southern California: concerns for lung health	69
Long-term outcomes of early exposure to repeated general anaesthesia in children with cystic fibrosis (CF-GAIN): a multicentre, open-label, randomised controlled phase 4 trial	66
Beyond the ventilator: rethinking daily evaluation of respiratory drive and effort	65
Type 2 inflammation biomarkers and their association with response to dupilumab in COPD (BOREAS): an analysis of a randomised, placebo-controlled, phase 3 trial	65
Breathing barriers: bridging lung health, research, and awareness	64
Vanzacaftor–tezacaftor–deutivacaftor versus elexacaftor–tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from tw	64
Managing tuberculosis before the onset of symptoms	64
Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial	63
Clarithromycin for early anti-inflammatory responses in community-acquired pneumonia in Greece (ACCESS): a randomised, double-blind, placebo-controlled trial	62
Extracorporeal membrane oxygenation in adults receiving haematopoietic cell transplantation: an international expert statement	62
Society of Critical Care Medicine Critical Care Congress 2023	61
The effect of inhaled hypertonic saline on lung structure in children aged 3–6 years with cystic fibrosis (SHIP-CT): a multicentre, randomised, double-blind, controlled trial	61
Home monitoring in interstitial lung diseases	60
COVID-19—an infectious disease in the top five causes of death in Australia	60
Pioneering a paradigm shift in asthma management: remission as a treatment goal	59
Time-dependent bias when analysing COVID-19-associated pulmonary aspergillosis – Authors' reply	56
Correction to Lancet Respir Med 2022; published online Feb 25. https://doi.org/10.1016/S2213-2600(22)00045-5	56
E-cigarette company tactics in sports advertising	55
SIMPLIFYing cystic fibrosis treatment in a post-modulator era	54
Moving forward in IPF: lessons learned from clinical trials	54
Core outcome measurement instruments for use in clinical and research settings for adults with post-COVID-19 condition: an international Delphi consensus study	54
Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis	54
General population-based lung function trajectories over the life course: an accelerated cohort study	52
Common and rare variants and survival in idiopathic pulmonary fibrosis	52
Identification of phenotypes in paediatric patients with acute respiratory distress syndrome: a latent class analysis	51
Correction to Lancet Respir Med 2025; 13: 800–08	51
The importance of post-tuberculosis morbidity in high-income countries	51
Continuing ECMO with no possible transition to recovery or transplant	51
What is adequate preoxygenation? – Authors' reply	50
Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicent	50
Remission in chronic cough: an achievable target?	50
Rise in group A streptococcal infections in England	49
Waning immunity to SARS-CoV-2: implications for vaccine booster strategies	49
Cardiac and vascular serious adverse events following tixagevimab–cilgavimab	48
Tackling the global burden of lung disease through prevention and early diagnosis	48
Sanjay Ramakrishnan—several lucky turns to arrive at COPD	48
Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and	47
NUTRIREA-3: where to next?	47
Safety and efficacy of the intranasal spray SARS-CoV-2 vaccine dNS1-RBD: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial	47
Trial emulation with observational data in cystic fibrosis	47
Safety and efficacy of the epithelial sodium channel blocker idrevloride in people with primary ciliary dyskinesia (CLEAN-PCD): a multinational, phase 2, randomised, double-blind, placebo-controlled c	47
Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial	47
Reframing sepsis immunobiology for translation: towards informative subtyping and targeted immunomodulatory therapies	46
Continued enteral nutrition until extubation compared with fasting before extubation in patients in the intensive care unit: an open-label, cluster-randomised, parallel-group, non-inferiority trial	46
Prevention and management of thrombosis in hospitalised patients with COVID-19 pneumonia	46
Weaning from mechanical ventilation in intensive care units across 50 countries (WEAN SAFE): a multicentre, prospective, observational cohort study	46
Comparative outcomes of extracorporeal membrane oxygenation for COVID-19 delivered in experienced European centres during successive SARS-CoV-2 variant outbreaks (ECMO-SURGES): an international, multi	46

Perioperative lung expansion and pulmonary outcomes after abdominal surgery	45
Reflections 5 years on from the approval of ETI therapy	45
Surviving COVID-19: a familiar road to recovery?	44
Stubble: the Farmer's Bane	44
ECMO: more than just a bridge over troubled waters?	44
Use of lung-cancer trends for global and public health priorities	44
Oral corticosteroids for acute preschool wheeze	42
Effect of non-invasive ventilation after extubation in critically ill patients with obesity in France: a multicentre, unblinded, pragmatic randomised clinical trial	42
Patient in her 70s with COPD and asthma improving significantly since using monoclonal antibody dupilumab	42
Changes in rates of prescriptions for inhaled corticosteroids during the COVID-19 pandemic	42
Development of an asthma health-care burden score as a measure of severity and predictor of remission in SARP III and U-BIOPRED: results from two major longitudinal asthma cohorts	42
Symptoms, risk of future exacerbations, and response to long-term macrolide treatment in bronchiectasis: an observational study	42
European Lung Cancer Congress 2024	41
Chronic respiratory disease in Indigenous peoples: a framework to address inequity and strengthen respiratory health and health care globally	41
Correction to Lancet Respir Med 2024; 12: 544–55	41
Long-term efficacy and safety of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): extended follow-up of an open-label, multicentre, randomised,	41
Flavia Machado—a Latin American leader in sepsis	40
Guidelines might help reduce the burden of asthma in African children	40
Postoperative CPAP after major abdominal surgery – Authors' reply	40
Determinants of long-term outcomes in patients with COVID-19 supported with ECMO – Authors' reply	40
Correction to Lancet Respir Med 2023; published online Feb 3. https://doi.org/10.1016/S2213-2600(22)00491-X	39
Lifting the veil on humour and anaesthetics	39
Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial	39
US Senate announces planned gun reforms after latest school shooting	38
International guideline recommendations and eligibility criteria for home oxygen therapy	37
The upcoming influenza season and protection from vaccines	37
Surviving sepsis with multiple serious complications	37
Fighting sepsis: still a long way to go	37
Chronic thromboembolic pulmonary hypertension: realising the potential of multimodal management	36
Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomi	36
Neomi Shah—cracking the conundrum of sleep disorders	36
Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled,	36
High-dose rifampicin to treat tuberculosis infection: potential and pitfalls	35
Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study	35
Time to escalate quality assurance in small-cell lung cancer radiotherapy trials – Authors' reply	35
Community-acquired pneumonia: the best candidates for clarithromycin	35
The burden of respiratory syncytial virus in healthy term-born infants in Europe: a prospective birth cohort study	35
The carbon footprint of inhaled medications in Australia	35
Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study	35
C-reactive protein-guided treatment in pneumonia: charting a personalised approach – Authors’ reply	34
How Glasgow's 1957 tuberculosis screening programme could help countries today	34
The passage of Ireland's Human Tissue Act: challenges, consequences, and cross-border cooperation	34
Correction to Lancet Respir Med 2025; 13: 318–26	34
Preoxygenation strategies for intubation: a closer look at inclusion criteria and patient heterogeneity – Authors' reply	33
Unseen collateral damage: tackling preventable morbidity and mortality in family members of ICU decedents	33
Taladegib for the treatment of idiopathic pulmonary fibrosis (ENV-IPF-101): a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial	33
Home-based monitoring in chronic respiratory diseases: in search of Panacea	33
Clinical remission attainment, definitions, and correlates among patients with severe asthma treated with biologics: a systematic review and meta-analysis	32
Addressing the post-acute sequelae of SARS-CoV-2 infection: a multidisciplinary model of care	31
Lockdown as the mother of invention: disruptive technology in a disrupted time	31
SARS-CoV-2 infection and vaccine effectiveness in England (REACT-1): a series of cross-sectional random community surveys	31
Knowledge gaps in fibrotic interstitial lung disease in pan-Asian populations: data not missing at random?	31
Online mindfulness-based cognitive therapy for fatigue in patients with sarcoidosis (TIRED): a randomised controlled trial	31
Continued resuscitation at the scene versus early transport for refractory out-of-hospital cardiac arrest	31
Arrival of biosimilars in respiratory medicine: towards improved access to biologics for patients	30
Adjuvant chemotherapy for stage IA–IIA non-squamous, non-small-cell lung cancer identified as molecular high-risk by a 14-gene expression profile (AIM-HIGH): an international, randomised, phase 3 tria	30
It is time to include real-world effectiveness data on medicinal product labels	29
Discussions on VT4COVID	29
Understanding clinical and biological heterogeneity to advance precision medicine in paediatric acute respiratory distress syndrome	29
Convalescent plasma in outpatients with COVID-19	29
Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomise	29
US EPA strengthens PM2·5 air pollution limits	29
Tuberculosis prevalence: beyond the tip of the iceberg	29
Selonsertib in adults with pulmonary arterial hypertension (ARROW): a randomised, double-blind, placebo-controlled, phase 2 trial	29
Remdesivir saves lives. Were 3 years needed to learn that?	29
Concerns regarding a suggested long COVID paradigm	28
Outcome predictors and patient progress following delivery in pregnant and postpartum patients with severe COVID-19 pneumonitis in intensive care units in Israel (OB-COVICU): a nationwide cohort study	28
Correction Lancet Respir Med 2022; 10: 937–48	28
Living with spinal muscular atrophy while working in critical care	27
Concerning the use of aminoglycosides in ventilator-associated pneumonia – Authors' reply	27
Air pollution, climate change, and lung health in Europe	27
What is next for BCG revaccination to prevent tuberculosis?	26
European Respiratory Society International Congress 2024	26
Chronic obstructive pulmonary disease: new therapies and old needs	26
Confounding undermines inferences of preventive therapy effectiveness among subgroups of tuberculosis contacts	26
Opportunities and challenges of COPD tertiary prevention	26
Early postnatal high-dose fat-soluble enteral vitamin A supplementation for moderate or severe bronchopulmonary dysplasia or death in extremely low birthweight infants (NeoVitaA): a multicentre, rando	25
Navigating uncertainty: asthma biologics during pregnancy	25
Can the positive findings from POD1UM-304 improve patient care worldwide?	25
Foritinib in advanced ROS1-rearranged non-small-cell lung cancer in China: a multicentre, open-label, single-arm, phase 2 study	25
Treatment strategy for EGFR mutated NSCLC	25
Baseline characteristics of patients in the Chinese Bronchiectasis Registry (BE-China): a multicentre prospective cohort study	24
D-dimer thresholds in pulmonary embolism: avoiding one-size-fits-all	24
The importance of patient-reported outcomes and measures	24
Idiopathic inflammatory myopathies related lung disease in adults	24
Volcanic eruption in Tonga and effects on respiratory health	24
Effects of Janus kinase inhibitors in adults admitted to hospital due to COVID-19: a systematic review and individual participant data meta-analysis of randomised clinical trials	24
Addressing the origins and health effects of small lungs	23
COVID-19-related ARDS: one disease, two trajectories, and several unanswered questions	23
Tuberculosis, conflict, and displacement	23
Philip Morris International purchases Vectura	23
Sedative medications: an avoidable cause of asthma and COPD exacerbations?	23
Supporting families with tuberculosis during COVID-19 in Khayelithsa, South Africa	23
Correction to Lancet Respir Med 2022; 10: 327–36	23
Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster following three doses of CoronaVac: a multicentre, open	23